Related Experiment Video

Updated: Aug 15, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers

Lucilla Parnetti1, Alessia Lanari, Giorgio Silvestrelli

  • 1Section of Neurology, Department of Medical and Surgical Specialties and Public Health, University of Perugia, Ospedale Silvestrini, S. Andrea delle Fratte, 06156 Perugia, Italy. parnetti@unipg.it

Mechanisms of Ageing and Development
|November 9, 2005
PubMed

Insights

Predicting Alzheimer's disease (AD) progression in mild cognitive impairment (MCI) is crucial. Using cerebrospinal fluid (CSF) biomarkers, specifically amyloid beta 42, total tau, and phospho-tau, can accurately identify patients likely to convert to AD.

Area of Science:

  • Neurology
  • Biochemistry
  • Geriatrics

Background:

  • Mild cognitive impairment (MCI) is a heterogeneous syndrome with varying progression rates.
  • Accurate prediction of MCI conversion to Alzheimer's disease (AD) is a clinical priority.
  • Cerebrospinal fluid (CSF) biomarkers, including amyloid protein (Abeta42), total tau (h-tau), and phospho-tau (p-tau), show promise in predicting MCI conversion.

Purpose of the Study:

  • To evaluate the utility of CSF biomarkers in predicting MCI conversion to AD in a routine clinical setting.
  • To assess the diagnostic accuracy of elevated levels of Abeta42, h-tau, and p-tau in predicting AD progression.
  • To differentiate between MCI patients who convert to AD and those who remain stable.

Main Methods:

  • A cohort of 273 patients with cognitive impairment was assessed.
  • 180 patients underwent complete diagnostic evaluation, including CSF biomarker analysis (Abeta42, h-tau, p-tau) via ELISA.
  • Patients were followed for 1 year to determine conversion to dementia or stability.

Main Results:

  • At baseline, 38% of MCI subjects had pathological levels in two or more CSF biomarkers.
  • After 1 year, 11 MCI patients converted to dementia; 10 of these had >=2 pathological CSF biomarkers, with high p-tau.
  • 29 out of 33 stable MCI patients (88%) had no or only one pathological CSF biomarker.
  • Elevated CSF biomarkers reliably predicted MCI conversion to AD and identified stable MCI.

Conclusions:

  • Pathological levels in two or more CSF biomarkers (Abeta42, h-tau, p-tau) are reliable predictors of MCI conversion to AD.
  • CSF biomarker analysis can accurately identify MCI patients who will progress to AD and those who will remain stable.
  • This approach supports the use of CSF biomarkers in routine clinical practice for managing MCI and predicting AD.

More Related Videos

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure08:40

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Published on: March 21, 2017

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...